Global Molecular Point of Care Devices Market Report 2020, Featuring Key Players Abbott Laboratories, bioMrieux SA, Credo Biomedical Pte. Ltd. and Oxford Nanopore Technologies Ltd. – ResearchAndMarkets.com
Monday, 25 May 2020, 07:25:00
DUBLIN–(BUSINESS WIRE)–The “Global Molecular Point of Care (mPOC) Devices Market 2020-2024” report has been added to ResearchAndMarkets.com’s offering. The molecular point of care (mPOC) devices market is poised to grow by $ 816.62 million during 2020-2024 progressing at a CAGR of 15% during the forecast period. The market is driven by the increasing prevalence of chronic and infectious diseases and the increasing number of M&A activities. This study identifies the rising number of produc
— Business Wire
Abbott Laboratories : Wins Contract to Supply Millions of Antibody Tests to UK Government | MarketScreener
Thursday, 21 May 2020, 19:29:01
By Stephen Nakrosis Abbott Labs on Thursday said it was awarded a contract to supply millions of its laboratory-based IgG antibody tests to National Health Service laboratories in the U.K…. | May 21, 2020
Abbott Labs pushes back on criticism that company’s rapid COVID-19 test is inaccurate
Monday, 18 May 2020, 16:16:49
After the Food and Drug Administration said last week that it is investigating preliminary data suggesting Abbott Laboratories’ coronavirus tests are inaccurate, a company executive addressed the New York University study that prompted the probe.
— Fox News
FDA Halts Bill Gates-Backed COVID-19 Testing Program
Sunday, 17 May 2020, 01:00:00
FDA Halts Bill Gates-Backed COVID-19 Testing Program Tyler Durden Sat, 05/16/2020 – 21:00 About a month after Bill Gates criticized President Trump’s decision to suspend funding to the World Health Organization (WHO), the federal government has just halted a Seattle-based COVID-19 testing program backed by Gates. What are the odds, right? “Please discontinue patient testing and return of diagnostic results to patients until proper authorization is obtained,” the Food & Drug Administration (FDA) wrote in a memo, addressed to the Seattle Coronavirus Assessment Network (SCAN), according to The New York Times . SCAN posted an update on its website on Thursday (May 14) describing how the FDA had asked it to “pause” testing while it receives further guidance on new procedures for its COVID-19 test kits that collect samples at home. The FDA “recently clarified its guidance for home-based, self-collected samples to test for COVID-19. We have been notified that a separate federal emergency use authorization (EUA) is required to return results for self-collected tests,” the post read. “The FDA has not raised any concerns regarding the safety and accuracy of SCAN’s test, but we have been asked to pause testing until we receive that additional authorization.” An FDA spokesperson told The Times, the home collection test kits raised some concerns about “safety and accuracy that required the agency’s review.” The issue in the Seattle case appears to be that the test results are being used not only by researchers for surveillance of the virus in the community but that the results are also being returned to patients to inform them.
— Zero Hedge
Grubhub, Marriott International, Abbott Laboratories: Stocks That Defined the Week
Friday, 15 May 2020, 23:54:00
Here are seven major companies whose stocks moved on the week’s news.
— The Wall Street Journal